The incidence of MET exon 14 mutation, which included METex14 and amplification, in NSCLCs is approximately 3%, and the mutation is more likely to occur in older female nonsmokers; both METex14 (HR = 2.156, P=0.026) and MET amplification (HR = 3.444, P=0.007) have been correlated with poor patient prognoses in NSCLC in multivariate analyses [38, 39]. Here, MET is linked to non-small cell lung carcinoma.